- Home
- IT vs JAZZ Comparison
IT vs JAZZ Comparison
Compare IT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IT | JAZZ |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | Ireland |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 16.1B |
| IPO Year | 2010 | 2007 |
Fundamental Metrics
Financial Performance| Metric | IT | JAZZ |
|---|---|---|
| Price | $207.73 | $233.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 22 |
| Target Price | $197.77 | ★ $295.50 |
| AVG Volume (30 Days) | ★ 957.3K | 815.9K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.66 | 0.04 |
| Revenue | ★ $2,021,441,000.00 | $1,618,693,000.00 |
| Revenue This Year | N/A | $12.55 |
| Revenue Next Year | $3.66 | $5.27 |
| P/E Ratio | ★ $19.36 | $5,797.13 |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $124.25 | $128.80 |
| 52 Week High | $256.90 | $266.38 |
Technical Indicators
Market Signals| Indicator | IT | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 59.41 |
| Support Level | $137.85 | $222.49 |
| Resistance Level | N/A | $241.39 |
| Average True Range (ATR) | 9.47 | 6.29 |
| MACD | -0.70 | 2.38 |
| Stochastic Oscillator | 36.58 | 84.46 |
Price Performance
Historical ComparisonAbout IT Gartner Inc.
Gartner provides independent research and analysis on information technology for chief information officers and other business executives who help plan companies' IT budgets. Its flagship Magic Quadrant reports inform many enterprises of their IT procurement decisions. Gartner also provides consulting services and holds some of the largest conferences in the IT industry. Around 80% of Gartner's revenue is generated from industry research.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.